Regeneron Pharma Earnings, Revenue Beat in Q4

Investing.com – Regeneron Pharma (NASDAQ:) reported on Thursday fourth quarter that beat analysts’ forecasts and revenue that topped expectations.

Regeneron Pharma announced earnings per share of $7.5 on revenue of $2.17B. Analysts polled by Investing.com anticipated EPS of $7.18 on revenue of $2.11B. That with comparison to EPS of $6.84 on revenue of $1.93B in the same period a year before. Regeneron Pharma had reported EPS of $6.67 on revenue of $2.05B in the previous quarter. Analysts are expecting EPS of $6.46 and revenue of $2.05B in the upcoming quarter.

Regeneron Pharma shares are down 0.88% from the beginning of the year , still down 15.80% from its 52 week high of $442.00 set on March 4, 2019. They are under-performing the Nasdaq which is up 5.19% year to date.

Regeneron Pharma follows other major Healthcare sector earnings this month

Regeneron Pharma’s report follows an earnings beat by J&J on January 22, who reported EPS of $1.88 on revenue of $20.75B, compared to forecasts EPS of $1.87 on revenue of $20.8B.

Merck&Co had beat expectations on Wednesday with fourth quarter EPS of $1.16 on revenue of $11.87B, compared to forecast for EPS of $1.15 on revenue of $11.95B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.